Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes

Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to include a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels.

High-risk breast cancer patients avoid MRIs that could improve early detection of disease

Nearly half of women at a high lifetime risk for breast cancer undergo routine mammograms at practices with onsite breast MR imaging capabilities, but MRI screenings are being vastly underused in the population, reaching just 6.6 percent of high-risk patients, a study in the Journal of Women’s Health states.